Plasma leptin, neuropeptide Y, ghrelin, and adiponectin levels and carotid artery intima media thickness in epileptic children treated with valproate

Basit Öğe Kaydı
dc.contributor.authorTokgoz, Huseyin
dc.contributor.authorAydin, Kursad
dc.contributor.authorOran, Bulent
dc.contributor.authorKiyici, Aysel
dc.date.accessioned2024-02-23T13:43:46Z
dc.date.available2024-02-23T13:43:46Z
dc.date.issued2012
dc.departmentNEÜen_US
dc.description.abstractWeight gain is a common side effect of valproate (VPA) treatment, although the mechanism is not clear. Abnormal weight gain and obesity are associated with dyslipidemia, hypertension, and atherosclerosis. Measurement of the common carotid artery intima media thickness (CAIMT) gives a picture of early arterial wall alterations and, currently, is considered a noninvasive marker of premature atherosclerosis. The aim of the present study was to evaluate plasma insulin, leptin, neuropeptide Y (NPY), ghrelin, and adiponectin levels in children with epilepsy treated with VPA and to evaluate these parameters for early atherosclerosis. Twenty prepubertal children with idiopathic epilepsy treated with VPA were enrolled in this study. Body mass index (BMI) and fasting insulin glucose ratio (FIGR) were calculated, and the plasma insulin, leptin, NPY, ghrelin, and adiponectin levels; the lipid profiles; and CAIMT were measured for all subjects before the treatment and after a follow-up period of 6 and 12 months. When pretreatment values were compared with those at the end of 6 and 12 months, the mean BMI values, plasma insulin, leptin, NPY levels, and FIGR were increased, whereas the plasma ghrelin and adiponectin levels, lipid profiles, and CAIMT did not change significantly at the end of 6 and 12 months. These results suggest that weight gain during VPA treatment may be related to increases in insulin, leptin, and NPY levels. Additionally, in this study, no increase in the risk for early atherosclerosis was determined by CAIMT in children with epilepsy treated with VPA.en_US
dc.identifier.doi10.1007/s00381-012-1788-7
dc.identifier.endpage1053en_US
dc.identifier.issn0256-7040
dc.identifier.issue7en_US
dc.identifier.pmid22645062en_US
dc.identifier.scopus2-s2.0-84863724282en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1049en_US
dc.identifier.urihttps://doi.org/10.1007/s00381-012-1788-7
dc.identifier.urihttps://hdl.handle.net/20.500.12452/10913
dc.identifier.volume28en_US
dc.identifier.wosWOS:000305465900013en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofChilds Nervous Systemen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdiponectinen_US
dc.subjectCarotid Artery Intima Media Thicknessen_US
dc.subjectEpilepsyen_US
dc.subjectGhrelinen_US
dc.subjectLeptinen_US
dc.subjectNeuropeptide Yen_US
dc.subjectValproateen_US
dc.titlePlasma leptin, neuropeptide Y, ghrelin, and adiponectin levels and carotid artery intima media thickness in epileptic children treated with valproateen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu